The Interval Between Initiation of Anti-tuberculosis Treatment in Patients with Culture-positive Pulmonary Tuberculosis and Receipt of Drug-susceptibility Test Results

Joon-Sung JOH; Chang-Hoon LEE; Ji-Eun LEE; Young-Kil PARK; Gill-Han BAI; Eui-Chong KIM; Sung-Koo HAN; Young-Soo SHIM; Jae-Joon YIM.
Journal of Korean Medical Science ; : 26-29, 2007.
Artículo en Inglés | WPRIM | ID: wpr-107136

Documentos relacionados

  1. Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents.
  2. Pharmacodynamics and Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.
  3. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
  4. [Preclinical and clinical trials of the new tuberculosis drug perchlozon].
  5. Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
  6. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
  7. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
  8. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies.
  9. Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
  10. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].